Tofacitinib for Treatment of Alopecia Areata: Real-world Evidence and Factors Associated with Therapeutic Response
DOI:
https://doi.org/10.2340/actadv.v102.2036Abstract
Abstract is missing (Short communication)
Downloads
References
Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 2018; 78: 1-12.
https://doi.org/10.1016/j.jaad.2017.04.1141 DOI: https://doi.org/10.1016/j.jaad.2017.04.1141
Hordinsky M, Donati A. Alopecia areata: an evidence-based treatment update. Am J Clin Dermatol 2014; 15: 231-246.
https://doi.org/10.1007/s40257-014-0086-4 DOI: https://doi.org/10.1007/s40257-014-0086-4
Lalosevic J, Gajic-Veljic M, Bonaci-Nikolic B, Stojkovic Lalosevic M, Nikolic M. Combined intravenous pulse and topical corticosteroid therapy for severe alopecia areata in children: comparison of two regimens. Dermatol Ther 2019; 32: e13092.
https://doi.org/10.1111/dth.13092 DOI: https://doi.org/10.1111/dth.13092
Phan K, Ramachandran V, Sebaratnam DF. Methotrexate for alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol 2019; 80: 120-127.e2.
https://doi.org/10.1016/j.jaad.2018.06.064 DOI: https://doi.org/10.1016/j.jaad.2018.06.064
Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2019; 33: 850-856.
https://doi.org/10.1111/jdv.15489 DOI: https://doi.org/10.1111/jdv.15489
Dhillon S. Tofacitinib: a review in rheumatoid arthritis. Drugs 2017; 77: 1987-2001.
https://doi.org/10.1007/s40265-017-0835-9 DOI: https://doi.org/10.1007/s40265-017-0835-9
Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI insight 2016; 1: e89776.
https://doi.org/10.1172/jci.insight.89776 DOI: https://doi.org/10.1172/jci.insight.89776
Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol 2017; 76: 22-28.
https://doi.org/10.1016/j.jaad.2016.09.007 DOI: https://doi.org/10.1016/j.jaad.2016.09.007
Yu D-A, Kim YE, Kwon O, Park H. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: a systematic review and meta-analysis. Indian J Dermatol Venereol Leprol 2021; 87: 621-627.
https://doi.org/10.25259/IJDVL_975_19 DOI: https://doi.org/10.25259/IJDVL_975_19
Olsen EA, Canfield D. SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss. J Am Acad Dermatol 2016; 75: 1268-1270.
https://doi.org/10.1016/j.jaad.2016.08.042 DOI: https://doi.org/10.1016/j.jaad.2016.08.042
Liu LY, King BA. Tofacitinib for the treatment of severe alopecia areata in adults and adolescents. J Investig Dermatology Symp Proc 2018; 19: 18-20.
https://doi.org/10.1016/j.jisp.2017.10.003 DOI: https://doi.org/10.1016/j.jisp.2017.10.003
Wollenhaupt J, Lee E-B, Curtis JR, Silverfield J, Terry K, Soma K, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther 2019; 21: 89.
https://doi.org/10.1186/s13075-019-1866-2 DOI: https://doi.org/10.1186/s13075-019-1866-2
Kurosawa M, Nakagawa S, Mizuashi M, Sasaki Y, Kawamura M, Saito M, et al. A comparison of the efficacy, relapse rate and side effects among three modalities of systemic corticosteroid therapy for alopecia areata. Dermatology 2006; 212: 361-265.
https://doi.org/10.1159/000092287 DOI: https://doi.org/10.1159/000092287
Published
How to Cite
License
Copyright (c) 2022 Manuel Sanchez-Diaz, Pablo Diaz-Calvillo, Juan-Angel Rodriguez-Pozo, Jesús Tercedor-Sánchez, Maria-Rosa Cantudo-Cuenca, Alejandro Molina-Leyva, Salvador Arias-Santiago
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
